BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1604 related articles for article (PubMed ID: 25517309)

  • 1. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Domain order of a bispecific diabody dramatically enhances its antitumor activity beyond structural format conversion: the case of the hEx3 diabody.
    Asano R; Kumagai T; Nagai K; Taki S; Shimomura I; Arai K; Ogata H; Okada M; Hayasaka F; Sanada H; Nakanishi T; Karvonen T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    Protein Eng Des Sel; 2013 May; 26(5):359-67. PubMed ID: 23468569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo antitumor effects of recombinant bispecific antibodies based on humanized anti-EGFR antibody.
    Watanabe Y; Asano R; Arai K; Shimomura I; Ogata H; Kawaguchi H; Hayashi H; Ohtsuka H; Yoshida H; Katayose Y; Egawa S; Nakanishi T; Umetsu M; Yasui H; Ishida T; Imai K; Kudo T; Unno M; Kumagai I
    Oncol Rep; 2011 Oct; 26(4):949-55. PubMed ID: 21743971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells.
    Asano R; Kawaguchi H; Watanabe Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
    J Immunother; 2008 Oct; 31(8):752-61. PubMed ID: 18779744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent.
    Asano R; Sone Y; Makabe K; Tsumoto K; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
    Clin Cancer Res; 2006 Jul; 12(13):4036-42. PubMed ID: 16818703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells.
    Asano R; Watanabe Y; Kawaguchi H; Fukazawa H; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
    J Biol Chem; 2007 Sep; 282(38):27659-65. PubMed ID: 17644522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxic enhancement of a bispecific diabody by format conversion to tandem single-chain variable fragment (taFv): the case of the hEx3 diabody.
    Asano R; Ikoma K; Shimomura I; Taki S; Nakanishi T; Umetsu M; Kumagai I
    J Biol Chem; 2011 Jan; 286(3):1812-8. PubMed ID: 21097496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preferential heterodimerization of a bispecific diabody based on a humanized anti-EGFR antibody 528.
    Asano R; Sone Y; Ikoma K; Hayashi H; Nakanishi T; Umetsu M; Katayose Y; Unno M; Kudo T; Kumagai I
    Protein Eng Des Sel; 2008 Oct; 21(10):597-603. PubMed ID: 18621782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of the Fc fusion format to generate tag-free bi-specific diabodies.
    Asano R; Ikoma K; Kawaguchi H; Ishiyama Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
    FEBS J; 2010 Jan; 277(2):477-87. PubMed ID: 20015073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanocell targeting using engineered bispecific antibodies.
    Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
    MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive study of domain rearrangements of single-chain bispecific antibodies to determine the best combination of configurations and microbial host cells.
    Asano R; Kuroki Y; Honma S; Akabane M; Watanabe S; Mayuzumi S; Hiyamuta S; Kumagai I; Sode K
    MAbs; 2018; 10(6):854-863. PubMed ID: 29985753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of the bispecific antibody IgG subclass on T cell redirection.
    Kapelski S; Cleiren E; Attar RM; Philippar U; Häsler J; Chiu ML
    MAbs; 2019; 11(6):1012-1024. PubMed ID: 31242061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.
    Croasdale R; Wartha K; Schanzer JM; Kuenkele KP; Ries C; Mayer K; Gassner C; Wagner M; Dimoudis N; Herter S; Jaeger C; Ferrara C; Hoffmann E; Kling L; Lau W; Staack RF; Heinrich J; Scheuer W; Stracke J; Gerdes C; Brinkmann U; Umana P; Klein C
    Arch Biochem Biophys; 2012 Oct; 526(2):206-18. PubMed ID: 22464987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin.
    Müller D; Karle A; Meissburger B; Höfig I; Stork R; Kontermann RE
    J Biol Chem; 2007 Apr; 282(17):12650-60. PubMed ID: 17347147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycosylation pattern of humanized IgG-like bispecific antibody produced by recombinant CHO cells.
    Kim WD; Tokunaga M; Ozaki H; Ishibashi T; Honda K; Kajiura H; Fujiyama K; Asano R; Kumagai I; Omasa T; Ohtake H
    Appl Microbiol Biotechnol; 2010 Jan; 85(3):535-42. PubMed ID: 19652963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural considerations for functional anti-EGFR × anti-CD3 bispecific diabodies in light of domain order and binding affinity.
    Asano R; Nagai K; Makabe K; Takahashi K; Kumagai T; Kawaguchi H; Ogata H; Arai K; Umetsu M; Kumagai I
    Oncotarget; 2018 Mar; 9(17):13884-13893. PubMed ID: 29568402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Build-up functionalization of anti-EGFR × anti-CD3 bispecific diabodies by integrating high-affinity mutants and functional molecular formats.
    Asano R; Hosokawa K; Taki S; Konno S; Shimomura I; Ogata H; Okada M; Arai K; Onitsuka M; Omasa T; Nakanishi T; Umetsu M; Kumagai I
    Sci Rep; 2020 Mar; 10(1):4913. PubMed ID: 32188928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Full-length recombinant antibodies from
    Rashid MH
    MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional Domain Order of an Anti-EGFR × Anti-CD16 Bispecific Diabody Involving NK Cell Activation.
    Kuwahara A; Nagai K; Nakanishi T; Kumagai I; Asano R
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 81.